Current treatment options for recurrent nasopharyngeal cancer.
about
A Review: Proteomics in Nasopharyngeal CarcinomaTriplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma.Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinomaMulti-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens.Ginsenoside compound K induces apoptosis in nasopharyngeal carcinoma cells via activation of apoptosis-inducing factor.Identification of CD24 as a cancer stem cell marker in human nasopharyngeal carcinoma.MR imaging prediction of local control of nasopharyngeal carcinoma treated with radiation therapy and chemotherapySafety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.Activation of Akt/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma.Increased expression of IRS-1 is associated with lymph node metastasis in nasopharyngeal carcinoma.Effectiveness and toxicities of intensity-modulated radiotherapy for patients with locally recurrent nasopharyngeal carcinoma.Radioactive ¹²⁵I seed inhibits the cell growth, migration, and invasion of nasopharyngeal carcinoma by triggering DNA damage and inactivating VEGF-A/ERK signaling.Magnetic resonance imaging following endoscopic nasopharyngectomy with a potassium-titanyl-phosphate (KTP) laser for early locally recurrent nasopharyngeal carcinoma.Prognostic significance of tumor volume in locally recurrent nasopharyngeal carcinoma treated with salvage intensity-modulated radiotherapyAn analysis of brachytherapy with computed tomography-guided permanent implantation of Iodine-125 seeds for recurrent nonkeratin nasopharyngeal carcinoma.BRCC3 acts as a prognostic marker in nasopharyngeal carcinoma patients treated with radiotherapy and mediates radiation resistance in vitro.Overexpression of Kinesin Family Member 20A Correlates with Disease Progression and Poor Prognosis in Human Nasopharyngeal Cancer: A Retrospective Analysis of 105 Patients.Overexpression of acylglycerol kinase is associated with poorer prognosis and lymph node metastasis in nasopharyngeal carcinoma.Dosimetric analysis of isocentrically shielded volumetric modulated arc therapy for locally recurrent nasopharyngeal cancer.Phase II study of gemcitabine plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy.Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles.Role of leukemia inhibitory factor in nasopharyngeal carcinogenesis.Reduced RKIP enhances nasopharyngeal carcinoma radioresistance by increasing ERK and AKT activity.A model to predict the risk of lethal nasopharyngeal necrosis after re-irradiation with intensity-modulated radiotherapy in nasopharyngeal carcinoma patientsPDZ binding kinase (PBK) is a theranostic target for nasopharyngeal carcinoma: driving tumor growth via ROS signaling and correlating with patient survivalHeavy LIFting: tumor promotion and radioresistance in NPC.Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance.CDC42-interacting protein 4 promotes metastasis of nasopharyngeal carcinoma by mediating invadopodia formation and activating EGFR signaling.Epstein-Barr virus encoded microRNA BART7 regulates radiation sensitivity of nasopharyngeal carcinoma.Unknown primary cancer of the head and neck: a multidisciplinary approach.Refractory nasopharyngeal carcinoma: positron emission tomography combined with computed tomography-guided 125I seed implantation therapy after repeated traditional radiochemotherapy.The increased expression of TCF3 is correlated with poor prognosis in Chinese patients with nasopharyngeal carcinoma.ACR Appropriateness criteria® for nasopharyngeal carcinoma.Endoscopic nasopharyngectomy in recurrent nasopharyngeal carcinoma: a case series, literature review, and pooled analysis.AHNS Series - Do you know your guidelines? Principles of treatment for nasopharyngeal cancer: A review of the National Comprehensive Cancer Network guidelines.Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing oxidative stress.Reduced expression of polymeric immunoglobulin receptor (pIgR) in nasopharyngeal carcinoma and its correlation with prognosis.Improved antitumor effect of ionizing radiation in combination with rapamycin for treating nasopharyngeal carcinoma.Salvage Intensity-Modulated Radiation Therapy (IMRT) for Locally Recurrent Nasopharyngeal Cancer after Definitive IMRT: A Novel Scenario of the Modern Era.The importance of early diagnosis in patients with maxillary sinus carcinoma.
P2860
Q26800017-B4F6184D-5A99-406B-B151-50875BC340D3Q33404307-50B1C7D0-3732-46F8-A95A-97D296C79BDBQ33428455-E3B1B58F-7B87-41AE-BC06-D8F4C334A955Q33439361-D4F2C1B4-A647-45D1-BB57-568ADC169600Q33614100-32C5179A-8958-454D-B9E4-E42407BB32D8Q33793359-A6CFE657-A36F-481D-8E4C-D23FFA6AC179Q33823256-7DCF9D11-91E8-432A-A5A4-AC8CC7B96715Q34074410-93B09921-6E39-4180-A99E-2DCEF3DFA676Q34105105-F8F836C1-3CF4-4C13-BFB3-D00A2B23BABDQ34371614-80BDE2CB-5527-409A-80A6-7D2B277C0C43Q34989498-219BEDFB-9EE0-4C45-8A8F-7A9EB10F194FQ34989673-9C8C530A-9FBE-4A72-84D4-75955186CC7CQ35001984-2AC2C04D-FE09-492A-8219-2A886B47A489Q35558480-A5B6E1EA-B7C9-48AD-A9C4-8ED0480A4E5CQ35593518-7AA0DAE2-7689-463A-AB18-0E5001FD9483Q35879933-D79CE643-D3EB-456D-8236-79FEE0E1EF07Q36247439-C1F9AEF4-6316-44B1-A540-6317F8FC16D7Q36834485-1B2D94AE-39A1-4467-BC8E-F2A94F43C120Q36897935-973654D4-93E4-4E79-9906-AC1E38782618Q36915011-4BA1C953-B7A7-40FB-9594-6E138AB6CC1CQ36997612-2510A7D6-3A7D-46FF-9A59-08DCD0771A2FQ36997722-89ACDAAD-71F5-4217-8E9F-7A21D45F1955Q36998275-66BCC594-C4D1-4FDA-8942-17FC1A9D9E3FQ37054739-A68D9A78-EBA5-4308-95FA-ED3DFC4DB0E6Q37295736-CC058471-D2F1-4F1D-BD57-9DCA6A8215B2Q37384033-694BEA28-BBE2-421F-933B-1143B6530805Q37384107-072B5E9F-7CDF-489B-B19F-AC9767D346DFQ37611019-EB34D0EF-935B-4FAF-9C9C-9A257C3320CAQ37746309-877F0449-E7E8-4EB3-9CDC-64BFA788B2A0Q37842965-AA3007BB-3614-4FB9-A9FA-FD938E38B7D9Q38110174-21D2DB46-E0A7-4156-8D43-0BA6E011F577Q38376290-60A473EE-31F6-4EFE-8935-168517847434Q38821590-5D16CCF3-B597-429E-8C6D-375DFBA24426Q39013914-ADC258E0-BC45-49E5-9693-11CEF2793276Q39023470-6E1522D9-1FDA-486E-B999-7E1BA5FA4907Q39025516-6144C5AA-6282-43E9-94F4-DC15F4BBF97AQ40890533-01F8769F-8058-44A8-A374-CB0372AE671CQ40979448-68B004E3-8990-4928-80CE-3A338BCE4987Q41063029-19C2BC10-DF75-483A-8F16-F68078A810B6Q41397705-10A7302A-F307-4551-824F-A5952E849554
P2860
Current treatment options for recurrent nasopharyngeal cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current treatment options for recurrent nasopharyngeal cancer.
@en
Current treatment options for recurrent nasopharyngeal cancer.
@nl
type
label
Current treatment options for recurrent nasopharyngeal cancer.
@en
Current treatment options for recurrent nasopharyngeal cancer.
@nl
prefLabel
Current treatment options for recurrent nasopharyngeal cancer.
@en
Current treatment options for recurrent nasopharyngeal cancer.
@nl
P2093
P2860
P921
P1476
Current treatment options for recurrent nasopharyngeal cancer
@en
P2093
Alessandra Rinaldo
Alfio Ferlito
Ashok R Shaha
Carlos Suárez
Johannes A Langendijk
P2860
P2888
P304
P356
10.1007/S00405-010-1385-X
P50
P577
2010-09-24T00:00:00Z